ebook_ADHD2019_spanish

25. Naaijen J, Lythgoe DJ, Amiri H, Buitelaar JK, Glennon JC. Fronto-striatal glutamatergic compounds in compulsive and impulsive syndromes: a review of magnetic resonance spectroscopy studies. Neurosci Biobehav Rev. 2015;52:74-88. 26. Brown RE, Stevens DR, Haas HL. The physiology of brain histamine. Prog Neurobiol. 2001;63(6):637-72. 27. Miyazaki C, Koyama M, Ota E, Swa T, Mlunde LB, Amiya RM, et al. Allergic diseases in children with at- tention deficit hyperactivity disorder: a systematic review and meta-analysis. BMC Psychiatry. 2017;17(1):120. 28. Sadek B, Saad A, Sadeq A, Jalal F, Stark H. Histamine H3 receptor as a potential target for cognitive symptoms in neuropsychiatric diseases. Behav Brain Res. 2016;312:415-30. 29. Moorthy G, Sallee F, Gabbita P, Zemlan F, Sallans L, Desai PB. Safety, tolerability and pharmacokinetics of 2-pyridylacetic acid, a major metabolite of betahistine, in a phase 1 dose escalation study in subjects with ADHD. Biopharm Drug Dispos. 2015;36(7):429-39. 30. Potter AS, Newhouse PA, Bucci DJ. Central nicotinic cholinergic systems: a role in the cognitive dysfunc- tion in attention-deficit/hyperactivity disorder? Behav Brain Res. 2006;175(2):201-11. 31. Williams NM, Franke B, Mick E, Anney RJ, Freitag CM, Gill M, et al. Genome-wide analysis of copy number variants in attention deficit hyperactivity disorder: the role of rare variants and duplications at 15q13.3. Am J Psychiatry. 2012;169(2):195-204. 32. Potter AS, Schaubhut G, Shipman M. Targeting the nicotinic cholinergic system to treat attention-deficit/ hyperactivity disorder: rationale and progress to date. CNS Drugs. 2014;28(12):1103-13. 33. Fair DA, Bathula D, Nikolas MA, Nigg JT. Distinct neuropsychological subgroups in typically developing youth inform heterogeneity in children with ADHD. Proc Nat Acad Sci U.S.A. 2012;109(17):6769-6774. 34. Coghill DR, Seth S, Matthews K. A comprehensive assessment of memory, delay aversion, timing, inhi- bition, decision making and variability in attention deficit hyperactivity disorder: advancing beyond the thre- e-pathway models. Psychol Med. 2014;44(9):1989-2001. 35. Douglas VI. Stop, look and listen: the problem of sustained attention and impulse control in hyperactive and normal children. Can J Behav Sci. 1972;4(4):259-282. 36. Sergeant J. The cognitive-energetic model: an empirical approach to attention-deficit hyperactivity disor- der. Neurosci Biobehav Rev. 2000;24(1):7-12. 37. Barkley RA. Behavioral inhibition, sustained attention, and executive functions: constructing a unifying theory of ADHD. Psychol Bull. 1997;121(1):65-94. 38. Sonuga-Barke EJ, Houlberg K, Hall M. When is "impulsiveness" not impulsive? The case of hyperactive children's cognitive style. J Child Psychol Psychiatry. 1994;35(7):1247-53. 39. Sonuga-Barke EJ. Psychological heterogeneity in AD/HD--a dual pathway model of behaviour and cog- nition. Behav Brain Res. 2002;130(1-2):29-36. 40. Durston S, van Belle J, de Zeeuw P. Differentiating frontostriatal and fronto-cerebellar circuits in atten- tion-deficit/hyperactivity disorder. Biol Psychiatry. 2011;69(12):1178-84. 41. Sergeant JA. Modeling attention-deficit/hyperactivity disorder: a critical appraisal of the cognitive-ener- getic model. Biol Psychiatry. 2005;57(11):1248-55. 42. Logan GD, Cowan WB, Davis KA. On the ability to inhibit simple and choice reaction time responses: a model and a method. J Exp Psychol Hum Percept Perform. 1984;10(2):276-91. 43. Oosterlaan J, Logan GD, Sergeant JA. Response inhibition in AD/HD, CD, comorbid AD/HD + CD, anxious, and control children: a meta-analysis of studies with the stop task. J Child Psychol Psychiatry. 1998;39(3):411-25. Guía de la Federación Mundial de TDAH 41